JP2025525305A5 - - Google Patents
Info
- Publication number
- JP2025525305A5 JP2025525305A5 JP2024570660A JP2024570660A JP2025525305A5 JP 2025525305 A5 JP2025525305 A5 JP 2025525305A5 JP 2024570660 A JP2024570660 A JP 2024570660A JP 2024570660 A JP2024570660 A JP 2024570660A JP 2025525305 A5 JP2025525305 A5 JP 2025525305A5
- Authority
- JP
- Japan
- Prior art keywords
- mutein
- fusion protein
- protein
- domain
- serum albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22182401 | 2022-06-30 | ||
| EP22182401.4 | 2022-06-30 | ||
| EP22205669 | 2022-11-04 | ||
| EP22205669.9 | 2022-11-04 | ||
| PCT/EP2023/068109 WO2024003393A1 (en) | 2022-06-30 | 2023-06-30 | Fusion proteins with half life extending domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025525305A JP2025525305A (ja) | 2025-08-05 |
| JP2025525305A5 true JP2025525305A5 (enExample) | 2026-03-03 |
Family
ID=87136437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024570660A Pending JP2025525305A (ja) | 2022-06-30 | 2023-06-30 | 半減期延長ドメインを有する融合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250388696A1 (enExample) |
| EP (1) | EP4547708A1 (enExample) |
| JP (1) | JP2025525305A (enExample) |
| CN (1) | CN119487061A (enExample) |
| AU (1) | AU2023301542B2 (enExample) |
| CA (1) | CA3253055A1 (enExample) |
| WO (1) | WO2024003393A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024401183A1 (en) * | 2023-12-12 | 2026-04-30 | Navigo Proteins Gmbh | Novel serum albumin-binding fusion proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013148966A1 (en) * | 2012-03-28 | 2013-10-03 | Amylin Pharmaceuticals, Llc | Transmucosal delivery of engineered polypeptides |
| WO2019091918A1 (en) * | 2017-11-07 | 2019-05-16 | Navigo Proteins Gmbh | Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer |
| CA3139164A1 (en) * | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| CA3184995A1 (en) * | 2020-07-16 | 2022-01-20 | Navigo Proteins Gmbh | Serum stable binding proteins for human her2 for theranostic applications |
-
2023
- 2023-06-30 AU AU2023301542A patent/AU2023301542B2/en active Active
- 2023-06-30 WO PCT/EP2023/068109 patent/WO2024003393A1/en not_active Ceased
- 2023-06-30 JP JP2024570660A patent/JP2025525305A/ja active Pending
- 2023-06-30 US US18/880,225 patent/US20250388696A1/en active Pending
- 2023-06-30 EP EP23737978.9A patent/EP4547708A1/en active Pending
- 2023-06-30 CN CN202380050753.0A patent/CN119487061A/zh active Pending
- 2023-06-30 CA CA3253055A patent/CA3253055A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7857274B2 (ja) | 多重特異性分子 | |
| JP7140861B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| JP2020506898A5 (enExample) | ||
| Müller et al. | Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain | |
| JP2021526816A5 (enExample) | ||
| JP2022524338A5 (enExample) | ||
| JP2021505155A (ja) | 多重特異性分子及びその使用 | |
| WO2020114478A1 (zh) | Cd3抗体及其药物用途 | |
| JPH02500329A (ja) | ターゲット化多機能蛋白質 | |
| WO2020114479A1 (zh) | 多特异性蛋白分子 | |
| JP2020522267A (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP2024507540A5 (enExample) | ||
| JP2025120179A (ja) | タンパク質を多量体化する変異体ドメイン及びその分離 | |
| KR20230141817A (ko) | 이중특이 항체 | |
| JP2016520053A5 (enExample) | ||
| JP2020519696A (ja) | 多重特異性タンパク質薬物およびそのライブラリー、ならびに製造方法と使用 | |
| JP2024507693A5 (enExample) | ||
| JP2015520172A5 (enExample) | ||
| CN115028719B (zh) | 血清白蛋白结合纳米抗体及其制备方法与应用 | |
| AU2014241891B2 (en) | Ribotoxin molecules derived from sarcin and other related fungal ribotoxins | |
| IL305186A (en) | Compounds and methods for extending half life of biomolecules | |
| CN117843776B (zh) | 抗体分子、核酸、制药用途及炎性疾病治疗方法 | |
| CN117820475B (zh) | 针对il-17a的新型纳米抗体、药物、制备、方法及应用 | |
| CN108300725A (zh) | 可溶性单链抗体超抗原融合基因及蛋白和其制备与应用 |